ArticleBMC cancer2026
Circulating N6-methyladenosine RNA as a diagnostic and a stage-associated prognostic biomarker in colorectal cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundExtracellular vesicle (EV)-based liquid biopsy is increasingly recognized as a promising strategy for cancer diagnosis and prognosis, as EVs carry abundant, stable biomolecular cargo. N6-methyladenosine (m6A), the most prevalent modification in eukaryotic intracellular RNA, plays a critical role in regulating diverse cellular processes and has been implicated in tumor initiation and progression. However, the potential of EV-associated m6A-modified RNA (EV-m6A RNA) as a clinically useful biomarker for cancer detection remains unclear.
methodsEV-RNA was isolated from tumor tissues and matched serum samples collected from 76 colorectal cancer (CRC) patients. Serum samples from 30 healthy donors were included as controls. Serum EVs were prepared using the ExoQuick™ precipitation reagent. EV-RNA was extracted using Trizol reagent, and EV-m6A RNA levels were quantified using an enzyme-linked immunosorbent assay (ELISA).
resultsPrecipitation-enriched serum particles (PESPs) isolated from CRC patients and healthy donors were identified as CD9(+)/CD63(+)/ALIX(+) small particles, with a mean particle diameter of 60-70 nm. The ApoB expression was detectable in PESPs. The mean PESP concentration and PESP-RNA yield were significantly higher in CRC patients than in healthy controls (PESP concentration: 11 ± 8 × 10
conclusionThese findings support circulating PESP-m6A RNA levels as a feasible and noninvasive biomarker for CRC diagnosis, with additional potential for liquid biopsy-based prognostication and longitudinal disease monitoring.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.